KPTI — Karyopharm Therapeutics Inc

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About Karyopharm Therapeutics Inc

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$8.97
Market Cap$183M
Float18.1M
Shares Outstanding22.7M
Price/Sales (TTM)1.21
vs. Analyst Target+50.5% to analyst PT
Profit Margin-129.02%
Operating Margin (TTM)-76.31%
Revenue (TTM)$151M
Dividend RateNone
Analyst Target Price$13.50 (7 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 $108M -$196M $105M -$168M
2021 $210M -$124M $206M -$97.0M
2022 $157M -$165M $152M -$139M
2023 $146M -$143M $141M -$118M
2024 $145M -$76.4M $139M -$38.6M
2025 $146M -$196M $140M -$150M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Jun 2025 $37.9M -$37.3M
Sep 2025 $44.0M -$33.1M
Dec 2025 $34.1M -$102M
Mar 2026 $35.1M -$22.4M

Ownership & Float

Insider Ownership4.5%
Institutional Ownership78.0%
Short Float29.2%
% of All Funds Holding0.91%
Number of Funds Holding75

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$7.88Near-term / short-term trend
Weekly40-Week SMA$7.10Medium-term trend
Weekly80-Week SMA$7.05Cyclical trend (business cycle)
Weekly200-Week SMA$22.47Secular trend (multi-year)
Monthly10-Month SMA$7.12Near-term monthly trend
Monthly20-Month SMA$7.45Medium-term monthly trend
Monthly40-Month SMA$15.10Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$5.70 support 1.09x 0 months ago
$9.10 resistance 4.37x 1 months ago
$3.80 support 1.87x 8 months ago
$3.70 support 1.54x 12 months ago

Historical Earnings Reactions (51 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap 0.05% -0.06% 47.06% 11.23% -8.01%
1 Day 0.23% 0.38% 52.94% 16.95% -20.00%
1 Week 1.35% -0.29% 45.10% 64.99% -22.88%
2 Weeks 5.41% 2.03% 52.00% 97.88% -27.15%
1 Month 4.67% 0.85% 52.00% 71.09% -29.05%

Next earnings: August 2, 2026 (66 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan-1.6%30.8%13
Feb5.4%61.5%13
Mar2.1%53.8%13
Apr1.0%30.8%13
May-4.4%33.3%12
Jun1.2%58.3%12
Jul-2.7%41.7%12
Aug5.1%50.0%12
Sep-1.6%50.0%12
Oct-4.1%41.7%12
Nov12.6%66.7%12
Dec-3.1%38.5%13

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday 0.16% 49.1% 591
Tuesday -0.27% 45.4% 650
Wednesday 0.20% 49.8% 645
Thursday 0.06% 47.0% 634
Friday 0.07% 48.2% 633

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 78.0%

Insider Transactions — Smart Summary

Total insider ownership: 4.5%

12-Month Insider Activity Summary

Total Filings27
Net Value-$369,102.583
Net Shares Change-26,234
% of Float-0.1%
C-Suite Filings27
Clusters Detected3

Key Insiders

NameTitleNet ValueFilingsActivity
Paulson Richard A. President and CEO -$137,239.33 2 N/A
Poulton Stuart EVP, Chief Development Officer -$51,826.36 2 N/A
Rangwala Reshma EVP and Chief Medical Officer -$51,544.527 2 N/A
Cheng Sohanya Roshan EVP and Chief Commercial Officer -$46,399.338 2 N/A
Mano Michael EVP, CLOandSecretary -$35,704.897 2 N/A

Transaction Clusters

PeriodFilingsInsidersNet ValueSeniority
2025-09-04 – 2025-09-16 7 6 -$17,108 7 C-suite
2026-02-19 – 2026-03-03 7 6 -$296,998.501 7 C-suite
2026-05-15 – 2026-05-15 6 6 -$34,741.5 6 C-suite

Significant Filings

DateInsiderTitleNet ValuePrice After
2026-03-03 Rangwala Reshma EVP and Chief Medical Officer -$47,668.527 Transaction at $9.41, now -4.7%
2026-03-03 Poulton Stuart EVP, Chief Development Officer -$47,997.86 Transaction at $9.41, now -4.7%
2026-03-03 Paulson Richard A. President and CEO -$116,310.829 Transaction at $9.41, now -4.7%
2026-03-03 Mano Michael EVP, CLOandSecretary -$33,177.897 Transaction at $9.41, now -4.7%
2026-03-03 Cheng Sohanya Roshan EVP and Chief Commercial Officer -$43,321.338 Transaction at $9.41, now -4.7%
2026-05-15 Rangwala Reshma EVP and Chief Medical Officer -$3,876 Transaction at $9.50, now -5.6%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Karyopharm Therapeutics Inc (KPTI) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for KPTI on Trend Edge →